I have received all of my order plus the bonus pills. You not only met my
expectations but greatly exceeded them!
You properly set my expectations by providing me all the information that I would
need during the ordering process and then followed up regularly to insure that all
was occurring as it should.
Your focus on customer service is outstanding and has won me over as a long time
customer. I have already recommended you to two of my friends and will continue to
do so in the future. I am also very pleased with the quality of your product and
accompanying reference materials that I received with my order.
I will do all of my medical business through your firm from this point forward.
Thank you for your proactive efforts and strong customer focused business
practices. I can honestly say my purchase experience has been outstanding!
- Sincerely, Lloyd
ABC NewsReview Challenges Tamiflu EfficacyABC NewsA new review of the influenza drug oseltamivir (Tamiflu) has raised questions about both the efficacy of the medication and the commitment of its maker to supply enough data for claims about the drug to be evaluated by independent experts.
Local doctor says data suggests Tamiflu is not as effective at shortening flu ... - ABC Action News
ABC Action NewsLocal doctor says data suggests Tamiflu is not as effective at shortening flu .
Tamiflu Data Called Inconsistent, Underreported - Medscape
Tamiflu Data Called Inconsistent, UnderreportedMedscapeJanuary 20, 2012 — An international team of medical experts is calling into question the safety and efficacy of the anti-influenza drug oseltamivir (Tamiflu), saying that a review of unpublished data shows inconsistencies and that the drug's maker, .
Tamiflu 'effectiveness lacks proof' - Hayling Island Today
Daily MailTamiflu 'effectiveness lacks proof'Hayling Island Today“Tamiflu maker accused of secrecy over trial data,” reported The Independent today, while The Daily Telegraph said that scientists have challenged Roche, the manufacturer of the antiviral, to “prove Tamiflu works”.
Roche FY11 Profit Rises Despite Sales Drop; Sees Growth In FY12 - Update - NASDAQ
BloombergRoche FY11 Profit Rises Despite Sales Drop; Sees Growth In FY12 - UpdateNASDAQThis was despite challenges posed by unfavorable currency impact and a sharp decline in Tamiflu sales.